SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
Product Advantages:
Double inactivation and purification, duple guarantee for quality
Good immunogenicity, rapid induction of comprehensive response
Good safety, whole-course assurance
- <p style="white-space: normal"><strong>Double inactivation and purification, duple guarantee for quality</strong></p><p style="white-space: normal"> <img src="http://sd.powereasy.net:10089/upload/en/contentmanage/article/image/2021/12/16/ad853674cf924c6490be0f41f51a8b0f.jpg" title="ad853674cf924c6490be0f41f51a8b0f.jpg" alt="ad853674cf924c6490be0f41f51a8b0f.jpg" style="text-align: center"></p><p style="white-space: normal"><strong> Good immunogenicity, rapid induction of comprehensive response</strong></p><p style="white-space: normal">Humoral and cellular immune response can be elicited after whole-course immunization including protective neutralizing antibody, anti-S antibody and anti-N antibody produced in humoral immunity, and specific cellular immune response against whole virus particle, S-protein and N-protein. The neutralizing antibody, anti-S antibody and anti-N antibody could effectively clean the virus and prevent infection, the specific cellular immune response is significant for the construction of immune memory.</p><p style="white-space: normal"> <img src="http://sd.powereasy.net:10089/upload/en/contentmanage/article/image/2021/12/16/5f50faf9643d49e9a22a8a687c69f34d.jpg" title="5f50faf9643d49e9a22a8a687c69f34d.jpg" alt="5f50faf9643d49e9a22a8a687c69f34d.jpg" style="text-align: center"></p><p style="white-space: normal"><strong> Good safety, whole-course assurance</strong></p><p style="white-space: normal">According to the Council for International Organizations of Medical Sciences (CIOMS), the incidence of adverse reaction is categorized as: very common (≥10%), common, frequent (1%-10%, including 1%), uncommon, infrequent (0.1%-1%, including 0.1%), rare (0.01%-0.1%, including 0.01%), very rare (<0.01%). The adverse reactions of the product are described as follows:</p><p style="white-space: normal"> · Very common:</p><p style="white-space: normal"> Pain at injection site.</p><p style="white-space: normal"> · Common, frequent:</p><p style="white-space: normal"> Fatigue, pruritus at injection site, cough, fever and diarrhea.</p><p style="white-space: normal"> · Uncommon, infrequent:</p><p style="white-space: normal"> Redness at injection stie, swelling at injection site, nausea, mucosal disorder, hypersensitivity and etc.</p><p style="white-space: normal">The above-mentioned adverse reactions generally resolve spontaneously within 24-72 hours.</p><p style="white-space: normal"><img src="http://sd.powereasy.net:10089/upload/en/contentmanage/article/image/2021/12/16/ca50ad267c1147099e1525f1dbf9738f.jpg" title="ca50ad267c1147099e1525f1dbf9738f.jpg" alt="ca50ad267c1147099e1525f1dbf9738f.jpg" style="text-align: center"></p><p><br></p>
- <table cellspacing="0" width="496"><tbody><tr class="firstRow" style="height: 18px"><td width="496" valign="top" style="padding: 1px 7px 0; border-color: rgba(0, 0, 0, 1)"><p><span style="font-family: Calibri; font-size: 14px">Main Active Composition:</span></p></td></tr><tr style="height: 41px"><td width="496" valign="top" style="padding: 1px 7px 0; border-color: initial rgba(0, 0, 0, 1) rgba(0, 0, 0, 1)"><p><span style="font-family: Calibri; font-size: 14px">0.5ml per vial (syringe), 0.5ml per dose</span></p><p><span style="font-family: Calibri; font-size: 14px">containing 150U of inactivated SARS-CoV-2 (KMS1 strain) antigen (S protein).</span></p></td></tr><tr style="height: 126px"><td width="496" valign="top" style="padding: 1px 7px 0; border-color: initial rgba(0, 0, 0, 1) rgba(0, 0, 0, 1)"><p><span style="font-family: Calibri; font-size: 14px">Excipients: Aluminum hydroxide, glycine. There is no preservative in this product.</span></p><p><span style="font-family: Calibri; font-size: 14px">Description: Lightly milky-white suspension. Stratified precipitate may form which can be dispersed by shaking.</span></p><p><span style="font-family: Calibri; font-size: 14px">Storage: Store at 2-8</span><span style="font-family: "Cambria Math"; font-size: 14px">℃</span><span style="font-family: Calibri; font-size: 14px">, protected from light. Do not freeze.</span></p><p><span style="font-family: Calibri; font-size: 14px">Period of Validity: 24 months.</span></p><p><span style="font-family: Calibri; font-size: 14px">Packaging: In vials. 1 vial per box.</span></p></td></tr><tr style="height: 59px"><td width="496" valign="top" style="padding: 1px 7px 0; border-color: initial rgba(0, 0, 0, 1) rgba(0, 0, 0, 1)"><p><span style="font-family: Calibri; font-size: 14px">Indication:</span></p><p><span style="font-family: Calibri; font-size: 14px">The vaccine is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in susceptible individuals aged 18 and older.</span></p></td></tr><tr style="height: 23px"><td width="496" valign="top" style="padding: 1px 7px 0; border-color: initial rgba(0, 0, 0, 1) rgba(0, 0, 0, 1)"><p><span style="font-family: Calibri; font-size: 14px">Usage:</span></p><p><span style="font-family: Calibri; font-size: 14px">Individuals 18 years of age and older.</span></p></td></tr><tr style="height: 140px"><td width="496" valign="top" style="padding: 1px 7px 0; border-color: initial rgba(0, 0, 0, 1) rgba(0, 0, 0, 1)"><p><span style="font-family: Calibri; font-size: 14px">Dosage and Administration:</span></p><p><span style="font-family: Calibri; font-size: 14px">The primary immunization consists of two doses with an interval of 2-4 weeks, 0.5ml per dose. It has not been determined if a booster dose is required. ICORNVAC™ should be administered by intramuscular injection in the deltoid muscle of upper arm. Do not inject the vaccine intravascularly, subcutaneously or intradermally. The vaccine should not be mixed in the same syringe with any other vaccine or medicinal products.</span></p><p><br></p></td></tr></tbody></table>
Related Products
用户登录
还没有账号？
立即注册